Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals

Combination benefit of treatment with th

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

✍ Alison M. Bendele; Elizabeth S. Chlipala; Jon Scherrer; Janet Frazier; Gina Senn 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 695 KB

Objective. To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type II collagen-induced arthri